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Molecular mimicry of Campylobacter jejuni lipo-oligosaccharides (LOS) with gangliosides in nervous tissue 
is considered to induce cross-reactive antibodies that lead to Guillain-Barré syndrome (GBS), an acute poly-
neuropathy. To determine whether specific bacterial genes are crucial for the biosynthesis of ganglioside-like 
structures and the induction of anti-ganglioside antibodies, we characterized the C. jejuni LOS biosynthesis 
gene locus in GBS-associated and control strains. We demonstrated that specific types of the LOS biosynthesis 
gene locus are associated with GBS and with the expression of ganglioside-mimicking structures. Campylobacter 
knockout mutants of 2 potential GBS marker genes, both involved in LOS sialylation, expressed truncated 
LOS structures without sialic acid, showed reduced reactivity with GBS patient serum, and failed to induce an 
anti-ganglioside antibody response in mice. We demonstrate, for the first time, to our knowledge, that specific 
bacterial genes are crucial for the induction of anti-ganglioside antibodies.
Introduction
Autoimmune diseases are often preceded by an infectious illness. 
Molecular mimicry between microbial antigens and structures in 
host tissue has been implicated as a mechanism for triggering a cross-
reactive immune response after an infection (1). There is strong but 
indirect evidence for the pathogenic role of molecular mimicry in 
Guillain-Barré syndrome (GBS), an acute peripheral polyneuropathy 
and the most frequent cause of acute neuromuscular paralysis (2). 
Therefore, GBS is an excellent model disease to study both microbial 
and host factors involved in molecular mimicry.
The most frequently identified triggering agent of GBS is Cam-
pylobacter jejuni, a spiral-shaped Gram-negative bacterium (3, 4). 
C. jejuni is the leading causative agent of bacterial gastroenteritis 
worldwide, and it has recently also been associated with neoplastic 
disease of the gut (5). Acute-phase sera of GBS patients contain 
high titers of antibodies directed against gangliosides, membrane 
glycolipids that are highly enriched in nervous tissue (6). Biochem-
ical and serological studies have identified various ganglioside-
mimicking structures in the lipo-oligosaccharides (LOS) of the 
Campylobacter cell wall (7), and cross-reactive antibodies between 
Campylobacter LOS and gangliosides have been demonstrated in 
serum from GBS patients (6). Ganglioside-mimicking structures 
are found more frequently in neuropathy-associated C. jejuni 
strains than in strains isolated from patients with diarrhea (8). An 
important feature in ganglioside mimicry is the presence of sialic 
acid (N-acetylneuraminic acid) in both LOS and gangliosides (9).
Recently, we described a collection of geographically clustered 
but genetically heterogeneous C. jejuni strains isolated from Dutch 
patients with GBS or its variant, Miller Fisher syndrome (MFS) (10, 
11). Characterization of the isolates by phenotypic and molecular 
methods showed that no clustering of GBS/MFS–associated strains 
occurred when these were compared with control strains (10, 12).
The availability of a database with detailed serological and clinical 
data of the Dutch GBS/MFS patients provides a unique opportu-
nity for a systematic search for bacterial GBS/MFS–associated viru-
lence factors and correlations with specific immune responses and 
clinical presentation. We recently reported the association between 
the presence of the campylobacter sialic acid transferase-II (cst-II) 
gene and the expression of a GQ1b-like structure in the bacterial 
LOS (13). Based on these findings, we hypothesized that the pres-
ence of certain C. jejuni genes involved in LOS biosynthesis may be 
crucial for the induction of the anti-ganglioside immune response 
that leads to GBS. Therefore, we analyzed the LOS biosynthesis 
gene locus of GBS/MFS–associated C. jejuni strains. We found that 
specific types of the LOS biosynthesis locus are associated with 
GBS, and this finding led to the identification of potential GBS 
marker genes in C. jejuni. Functional analysis of Campylobacter gene 
knockout mutants, including mouse immunization experiments, 
demonstrated that these genes are crucial for the induction of 
anti-ganglioside antibodies.
Results
Specific classes of the LOS biosynthesis gene locus are associated with 
neuropathy and ganglioside mimicry. In C. jejuni, the genes involved in 
LOS biosynthesis are clustered in the LOS biosynthesis gene locus 
(LOS locus) (14). Variation in gene content of the LOS locus is 
an important mechanism for variation in LOS structure between 
different C. jejuni strains. Previously, we had described 3 different 
gene compositions or “classes” of the LOS locus in C. jejuni (15). 
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Since then, the DNA sequences of several additional C. jejuni LOS 
loci were deposited in GenBank (http://www.ncbi.nlm.nih.gov/
Genbank/), and there are now 5 distinct classes (Figure 1).
To study whether certain classes are more prevalent among 
neuropathy-associated C. jejuni strains, we determined the class of 
LOS locus (classes A–E) in a collection of 21 neuropathy-associated 
and 21 control C. jejuni strains isolated from patients with uncom-
plicated enteritis. All the strains used in this study were positive for 
1 of the 5 identified LOS locus classes. In addition, we analyzed the 
individual class A/B and class C genes by PCR RFLP and hybridiza-
tion analysis and found that the LOS gene content in the strains 
was in agreement with their class of LOS locus (data not shown). 
The class A LOS locus was overrepresented in the GBS-associated 
strains compared with the control strains (53% vs. 14%, P = 0.02; 
Table 1). In contrast, all 4 MFS-associated strains contained a 
class B locus, which was detected in only 33% of control strains 
(P = 0.03; Table 1) and 18% of GBS-associated strains (P < 0.01).
Studying the expression of ganglioside-like structures in rela-
tion to the class of LOS locus, we found that GM1-like structures 
were associated with a class A locus (P < 0.01), whereas GQ1b-like 
structures were predominantly expressed by strains with a class B 
locus (P < 0.01; Table 2). Although the class A locus was associated 
with both GBS and the presence of a GM1-like structure, a GM1-
like structure was not detected more frequently in GBS-associated 
strains (13 of 17 GBS strains vs. 12 of 21 control strains, P = 0.3). 
In 8 of 11 strains with a class D or E locus, ganglioside-like struc-
tures were not detected, which is in accordance with the absence of 
genes involved in the biosynthesis or transfer of sialic acid in these 
classes (Table 2; Figure 1). These results indicate that genes that 
are unique to the class A and B loci and genes that are involved in 
sialic acid biosynthesis or transfer may be crucial for the induction 
of neuropathogenic cross-reactive antibodies and may 
thus be considered as GBS marker genes.
Mutagenesis of putative GBS marker genes. To study wheth-
er potential GBS marker genes are indeed crucial for the 
induction of potentially neuropathogenic cross-reac-
tive antibodies, we constructed Campylobacter knockout 
mutants of 3 potential GBS marker genes. Open reading 
frame 11 (orf11) is unique to the class A and B loci (Fig-
ure 1). Its function is unknown, but sequence homology 
with an enzyme of Rhodobacter capsulatus suggests that 
orf11 encodes an acetyltransferase (16). The cst-II gene 
(orf7) encodes an enzyme (Cst-II) that is involved in the 
transfer of sialic acid to the LOS backbone. Orf10 encodes 
a CMP–sialic acid synthetase and is involved in the bio-
synthesis of the sialic acid donor used by Cst-II.
Cst-II and orf11 single mutants and an orf10/orf11 
double mutant were produced in 2 class A GM1-express-
ing GBS-associated C. jejuni strains (GB2 and GB11) by 
insertion of a chloramphenicol resistance (Cmr) cassette 
(Figure 2). The cassette was inserted with the same tran-
scriptional polarity as that of the mutated genes. For all 
mutants, possible double crossover events were verified 
by PCR. Southern blot analysis confirmed single integra-
tion of the Cmr cassette into the correct position on the 
chromosome (data not shown).
LOS structure analysis of WTs and mutants. To determine 
the effect of the gene inactivations on the LOS structure, 
we performed mass spectrometry analysis and identified 
a mixture of GM1- and GD1a-like structures for both 
GB2 and GB11 WT LOS (Figure 3). The sets of triply charged 
ions corresponding to GM1- and GD1a-like structures were of 
similar intensities (data not shown), which suggests that these 
2 structures are present in approximately equimolar amounts, 
assuming that the ionization efficiency is proportional to the 
amount of a species in the sample. Both the cst-II and the orf10/
orf11 mutants of GB2 and GB11 expressed a mixture of 3 nonsi-
alylated structures. The main fraction consisted of asialo-GM3, 
but asialo-GM2 and asialo-GM1 structures were also present (Fig-
ure 3). No structural differences were observed between the WTs 
and the orf11 mutants. This indicates that the truncated LOS 
structures as observed in the orf10/orf11 mutants were caused 
by the inactivation of orf10 and not orf11. Detailed results of the 
mass spectrometry analysis can be found in Supplemental Table 
2 (supplemental material available at http://www.jci.org/cgi/con-
tent/full/114/11/1659/DC1).
Table 1
LOS biosynthesis loci in C. jejuni strains from patients with GBS, 
MFS, and uncomplicated enteritis
 No. of strains associated with:
LOS locus  GBS MFS Enteritis P
class (n = 17) (n = 4) (n = 21) 
A (n = 12) 9 0 3 0.02A
B (n = 14) 3 4 7 0.03B
C (n = 5) 2 0 3 NS
D (n = 4) 2 0 2 NS
E (n = 7) 1 0 6 NS
AGBS vs. enteritis. BMFS vs. enteritis.
Figure 1
Genetic organization of the 5 different classes of the C. jejuni LOS biosynthe-
sis locus. The distance between the scale marks is 1 kb. The direction of the 
arrows indicates the direction of transcription. Corresponding homologous genes 
have the same number with a letter for the LOS locus class added. For orf1c 
and orf13c the corresponding Cj gene numbers of the “genome” strain NCTC 
11168 are given. The 5 LOS classes are based on DNA sequences of the fol-
lowing strains (GenBank accession number): class A: OH4384 (AF130984), 
OH4382 (AF167345), HS:4 (AF215659), HS:10 (AF400048), HS:19 (AF167344), 
HS:41 (AY044868); class B: HS:23 (AF401529), HS:36 (AF401528); class C: 
NCTC 11168 (AL139077), HS:1 (AY044156), HS:2 (AF400047); class D: LIO87 
(AF400669); class E: 81116 (AF343914 and AJ131360). The proposed functions 
for the orfs are described in Supplemental Table 1.
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Sialic acid mutants have a reduced reactivity with patient serum. Analy-
sis of the LOS by gel electrophoresis revealed faster-migrating LOS 
cores for the GB11 cst-II and orf10/orf11 mutants compared with 
the WT, confirming that these mutants have a truncated LOS (Fig-
ure 4A). The orf11 mutant LOS showed migration patterns identi-
cal to those of WT LOS. Results for the GB2 mutant were identical 
to those obtained with GB11 (data not shown). These findings are 
concordant with the structures found by mass spectrometry.
To determine whether the gene inactivations influenced the 
reactivity of the LOS with the antibodies in the serum from GBS 
patients, we performed an immunoblot analysis with the serum 
of the GBS patient from whose stools C. jejuni GB11 was isolated 
(GB11 patient) and WT and mutant purified LOS fractions. Previ-
ous studies showed that this serum contains high levels of anti-
GM1 antibodies (8). Reactivity of GB11 patient serum was reduced 
for the cst-II and orf10/orf11 mutants (Figure 4B) but remained the 
same for the orf11 mutant when compared with the WTs. For the 
cst-II and orf10/orf11 mutants, the reactivity with cholera toxin, a 
ligand for GM1-oligosaccharide structures, was almost completely 
lost (Figure 4C). These results indicate that genes involved in sialic 
acid biosynthesis and transfer are important for the expression 
of ganglioside-like LOS structures that are capable of inducing 
potentially pathogenic autoantibody responses. Although strain 
GB11 and the “genome” strain NCTC 11168 both express GM1 
mimics in their LOS (this was confirmed by their reactivity with 
cholera toxin; Figure 4C), the GB11 patient serum did not react 
with the LOS of NCTC 11168 (Figure 4B). This observation has 
been described previously (17). This observation illustrates the 
fine specificity of the antibody response in patient GB11, as the 
GB11 and NCTC 11168 strains have different LOS structures with 
a common GM1 mimic (Figure 3).
Sialic acid mutants fail to induce anti-ganglioside antibody responses 
in mice. To demonstrate that the truncated LOS structures in the 
mutants do not induce autoantibodies, we immunized GD2/
GM2 synthase knockout mice. These mice that lack complex 
gangliosides are immune-naive hosts that can be used to raise 
high-titer anti-ganglioside antibody responses (18). Immuniza-
tion with WT GB11 lyophilized whole bacteria resulted in high 
IgG serum responses against GD1a, a ganglioside containing 
2 sialic acid residues, in 2 of 2 mice (Figure 5A). We could not 
detect antibody reactivity against GM1 (data not shown). None 
of the mice injected with the cst-II and orf10/orf11 mutants pro-
duced anti-GD1a antibodies (Figure 5, B and C). However, all 6 
mice produced anti–asialo-GM1 antibodies, as can be expected 
from the truncated LOS structures in the cst-II and orf10/orf11 
mutants (Figure 5, F and G). Two of 3 mice immunized with the 
orf11 mutant strain produced GD1a antibodies (Figure 5D). Low 
asialo-GM1 titers were also found in 3 of 3 mice immunized with 
the orf11 mutant (Figure 5H). These results indicate that genes 
involved in sialylation of the LOS are crucial for the induction of 
cross-reactive anti-ganglioside antibodies.
Discussion
We have shown that specific types of the C. jejuni LOS biosynthesis 
gene locus (“LOS locus”) are clearly associated with immune-medi-
ated neuropathy and with the presence of ganglioside-mimicking 
structures in the LOS. Moreover, using Campylobacter gene knock-
out mutants, we demonstrate here, for the first time to our knowl-
edge, that genes involved in sialylation of the LOS are crucial for 
the induction of anti-ganglioside antibodies.
Diversity in the content of genes involved in LOS biosynthesis 
results in the variety of LOS structures that is observed in C. jejuni. 
In this study, we identified 2 new classes of the LOS locus, in addi-
tion to 3 previously described classes (15, 19). At the time of writing, 
DNA sequences of additional C. jejuni strains are accessible through 
GenBank, and new LOS gene combinations not reported earlier can 
be identified. However, all our strains had a positive PCR test for 1 
of the 5 LOS locus classes described in this study, which indicates 
that our tests completely covered the spectrum of different LOS loci 
present in this collection of Campylobacter strains.
The expression of ganglioside-mimicking structures in Cam-
pylobacter LOS is considered to be essential for the induction of 
autoantibodies that lead to GBS. Indeed, we previously reported that 
ganglioside-mimicking structures are present more frequently in 
neuropathy-associated strains than in strains isolated from patients 
with uncomplicated enteritis (8). In contrast, most of the Campylo-
bacter strains whose LOS structure has been chemically character-
ized and reported in the literature express ganglioside-mimicking 
structures. The number of strains that have been analyzed, however, 
is small and may not be representative. Our study demonstrates that 
C. jejuni needs specific gene combinations to express ganglioside 
mimics. Only 3 of the 5 identified classes of the LOS locus, i.e., class-
es A, B, and C, contain genes that are involved in the biosynthesis 
and transfer of sialic acid, an essential component of gangliosides. 
We showed that these LOS loci are present in the large majority of 
strains expressing ganglioside mimics, including the neuropathy-
associated strains, whereas class D and E loci are more frequently 
found in strains lacking ganglioside mimics. In 3 class D/E strains, 
Table 2
LOS biosynthesis loci and presence of ganglioside-like structures 
in C. jejuni strains
 No. of strains with a ganglioside-like
  structure in the LOSA
LOS locus  GM1  GQ1b  Other  None  P
type (n = 27) (n = 9) (n = 30) (n = 8)
A (n = 12) 12 1 10 0 <0.01B
B (n = 14) 9 8 14 0 <0.01C
C (n = 5) 5 0 3 0 NS
D (n = 4) 0 0 1 3 0.02D
E (n = 7) 1 0 2 5 <0.01D
AA strain can express more than 1 ganglioside-like structure in its LOS. 
Therefore, the sum of strains in a row (GM1 + GQ1b + other + none) is 
higher than the actual number of strains with the corresponding LOS 
locus type. BGM1 vs. non-GM1. CGQ1b vs. non-GQ1b. DNone vs. any.
Figure 2
Schematic representation of the mutants used in this study. Orf6 to 
orf13 of the class A LOS locus are displayed. The positions of the 0.7-kb 
Cmr cassette are indicated with gray arrows. Both orf10 and orf11 are 
inactivated in the orf10/orf11 mutant.
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ganglioside-like structures other than GM1 or GQ1b were detected 
(Table 2). The sera used in the serological assay for the detection of 
these “other” ganglioside-like structures may also react with asialo-
GM1–like structures lacking sialic acid. Therefore, the detection of 
an “other” ganglioside-like structure does not necessarily imply that 
the strain is able to synthesize and transfer sialic acid. However, we 
cannot exclude the possibility that some strains have both class D 
or E genes and sialic acid biosynthesis genes that have diverged from 
their homologues in classes A, B, and C.
Interestingly, we found that the class A locus is associated 
specifically with GBS and the presence of a GM1-like structure, 
whereas the class B locus is associated with MFS and the presence 
of a GQ1b-like structure. The presence of anti-GM1 antibodies has 
been shown to be associated with a preceding Campylobacter infec-
tion (3). We found that GM1-like structures can be expressed by 
strains with various LOS locus classes. However, the association of 
a class A LOS locus with both GBS and the presence of a GM1-like 
structure suggests that class A strains expressing GM1-like LOS 
structures are more likely to induce GBS compared with non-A 
strains with a GM1-like LOS.
MFS, a variant of GBS, has consistently been associated with 
preceding C. jejuni infection. Several authors have demonstrated 
that GQ1b-like structures occur more frequently in MFS-associ-
ated strains and are associated with anti-GQ1b antibody reactiv-
ity and the presence of oculomotor symptoms in patients with 
GBS or MFS (8, 20). Although GQ1b-like structures were detect-
ed in both class A and class B strains, we found that only the 
class B locus was significantly associated with the presence of a 
GQ1b-like structure and that all our MFS-associated strains con-
tained a class B locus. However, not all class B strains expressed 
GQ1b-like structures. This may be explained by mechanisms 
such as phase variation or point mutations that lead to gene 
inactivations resulting in the absence of expression of GQ1b-like 
structures in some class B strains (21, 22). In conclusion, we have 
now identified specific molecular substrates in C. jejuni that are 
involved in the induction of GBS or MFS.
To our knowledge, this is the first study that analyzed the LOS 
locus of a large collection of neuropathy-associated and control 
C. jejuni strains. Previously, it was demonstrated that 2 closely 
related GBS-associated strains contained a class A locus (16). Very 
recently, we demonstrated that the strain GB11 that we used in 
this study has probably acquired its class A locus through hori-
zontal gene transfer (17). Another recent report did not find an 
association between GBS and LOS biosynthesis genes using a 
whole-genome DNA microarray (23). This microarray, however, 
only contained LOS genes present in a class C locus and would 
therefore not be able to detect the association described here.
Based on the results of the LOS locus analysis, we hypothesized 
that genes unique to the class A and B loci or genes that are involved 
in sialic acid biosynthesis and transfer are crucial for the induction 
of neuropathogenic cross-reactive antibodies. To test this hypoth-
Figure 3
Molecular mimicry between gangliosides and LOS outer cores of WT 
and mutant C. jejuni strains. LOS outer core structures of GB2 and 
GB11 WT and mutant strains were determined by mass spectrometry 
analysis. The LOS outer core structure of the “genome” strain NCTC 
11168 was described by St. Michael et al. (35). Note that all strains 
express a mixture of different LOS structures. The cst-II and orf10/
orf11 mutants of GB2 and GB11 expressed not ganglioside mimics but 
a mixture of 3 nonsialylated structures. No structural differences were 
observed between the WTs and the orf11 mutants.
Figure 4
SDS-PAGE analysis of LOS from GB11 WT and mutants. The genome 
strain NCTC 11168 was included as a control. Lane 1, WT GB11; lane 
2, GB11 cst-II mutant; lane 3, GB11 orf10/orf11 mutant; lane 4, GB11 
orf11 mutant; lane 5, NCTC 11168. (A) Silver staining of the LOS 
revealed faster-migrating LOS cores for the GB11 cst-II and orf10/
orf11 mutants compared with the WT, indicating that these mutants 
have a truncated LOS. The orf11 mutant LOS showed migration pat-
terns identical to those of WT LOS. (B) A Western blot incubated with 
GB11 patient serum showed a reduced reactivity for the cst-II and 
orf10/orf11 mutants but unchanged reactivity for the orf11 mutant when 
compared with the WTs. (C) For the cst-II and orf10/orf11 mutants, the 
reactivity with cholera toxin, a ligand for GM1-oligosaccharide struc-
tures, was almost completely lost. Reactivity with the orf11 mutant 
remained unchanged.
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esis, we constructed a Campylobacter knockout mutant of orf11, 
encoding a putative acetyltransferase with unknown function in 
LOS biosynthesis and the only gene that is unique to class A and B 
loci. Several genes are involved in the sialylation of Campylobacter 
LOS (Supplemental Table 1). Inactivation of either of these genes 
will probably lead to identical changes in LOS structure; i.e., trun-
cated LOS lacking sialic acid. We constructed knockout mutants 
of 2 such genes: orf10, encoding a CMP–sialic acid synthetase, and 
cst-II. Cst-II, present in class A and B loci, encodes a bifunctional 
sialic acid transferase that has been characterized in detail and that 
has been associated with the presence of a GQ1b-like structure 
(13, 15, 24). Cst-II has a sialyltransferase homologue in the class 
C locus, called cst-III (53% identity), but the bifunctional (α-2,3/
α-2,8) sialyltransferase activity that is probably necessary for the 
biosynthesis of GQ1b-like structures has so far only been detected 
for cst-II (15). Orf10 was inactivated along with the adjoining orf11 
in a so-called double mutant (Figure 2). Because the orf11 single 
mutants did not show any differences compared with the WTs, we 
assumed that the differences observed in the orf10/orf11 double 
mutant were the result of the inactivation of orf10. Mutants were 
constructed of 2 class A GBS-associated strains that expressed 
GM1-like structures in their LOS. We were unsuccessful in our 
efforts to construct mutants of MFS-associated strains expressing 
GQ1b-like structures, since, unfortunately, these strains did not 
appear to be transformable (data not shown).
Mass spectrometry analysis revealed a mixture of 2 different 
sialylated ganglioside-mimicking structures in the WT GB2 and 
GB11 strains. Inactivation of cst-II and orf10 resulted in a mixture 
of 3 truncated LOS structures lacking sialic acid. Two of these 
structures lacked not only sialic acid, when compared with the 
WT, but also the outer Gal or Gal-GalNAc residues of the LOS 
backbone (Figure 3). This observation is consistent with the lower 
activity of the β-1,4-N-acetylgalactosaminyltransferase (CgtA) on 
nonsialylated acceptors that was previously reported for CgtA 
from C. jejuni OH4384 (16). Inactivation of orf11 did not result 
in differences in LOS structure compared with that in the WT 
strains. Therefore, the function, if any, of this gene in LOS biosyn-
thesis and in the pathogenesis of GBS remains unknown. In sum-
mary, mass spectrometry analysis revealed that genes involved in 
sialylation are necessary for the biosynthesis of ganglioside mimics 
in Campylobacter LOS. Other studies have demonstrated the role 
of cst-III (orf7c), neuB1 (orf8c), and neuC1 (orf9b and orf9c) in the 
synthesis of ganglioside mimics (21, 25, 26).
Inactivation of cst-II and orf10 resulted in reduced reactiv-
ity of GB11 patient serum with mutant LOS, providing sup-
port for their importance in the induction of autoantibodies in 
GBS. Although residual reactivity was seen, this was probably 
caused by anti–asialo-GM1 antibodies or anti-GM1 and anti-
GD1b antibodies that cross-react with asialo-GM1 structures in 
the mutant LOS. It has previously been demonstrated that the 
GB11 patient serum contains antibodies directed against GM1 
(high titer), asialo-GM1 (low titer), and GD1b (high titer), which 
all contain the terminal disaccharide Gal-GalNAc (8). Although 
nonsialylated glycoconjugates are present on nerve tissue, so far, 
anti–asialo-GM1 antibodies have not been associated with GBS. 
The complete absence of reactivity of cholera toxin with cst-II and 
orf10/orf11 mutant LOS further confirms the crucial role of cst-II 
and orf10 in the biosynthesis of ganglioside mimics.
The mouse immunization experiments conducted in this study 
provide additional evidence for the necessity of sialylation genes 
for the induction of autoantibodies. Both cst-II and orf10/orf11 
mutants failed to induce anti-ganglioside antibodies in mice, in 
contrast to the WT strains. Mice injected with the cst-II and orf10/
orf11 mutants produced serum antibodies against the nonsialylat-
ed glycoconjugate asialo-GM1, but these antibodies have not yet 
been associated with GBS. Anti-GD1a but no anti-GM1 antibod-
ies were detected in mice immunized with the GB11 WT strain. 
This is in contrast with earlier findings that GB11 also expresses 
a GM1-like LOS structure and that GB11 patient serum contains 
high levels of anti-GM1 antibodies. However, it has been observed 
previously that immunization with both GD1a and GM1 induced 
primarily anti-GD1a responses in mice, whereas rabbits only had 
Figure 5
Anti-glycolipid antibodies in serum of mice before and after immunization with WT and mutant GB11 C. jejuni strains. (A and D) When sialic acid 
was present on the LOS core (WT and orf11 mutant), anti-GD1a antibodies were induced in mice. (B and C) Anti-GD1a antibody responses were 
not detected in mice immunized with nonsialylated LOS (cst-II and orf10/orf11 mutants). (F and G) Nonsialylated LOS (cst-II and orf10/orf11 
mutants) induced high asialo-GM1 antibody responses. (E and H) Asialo-GM1 antibody responses were absent or low after immunization with 
the orf11 mutant and WT.
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anti-GM1 antibodies (27, 28). Thus, anti-ganglioside antibody 
responses may be species dependent.
The associations that we found are not absolute. As host factors 
also play an important role in the pathogenesis of GBS, infection 
with a C. jejuni strain that expresses ganglioside-like structures is 
not sufficient to trigger GBS. In addition, a variety of ganglioside 
mimics, produced by different LOS classes, have been associated 
with GBS with diverse clinical manifestations (8, 20, 29). Further-
more, it is not clear at present whether all bacterial factors involved 
in the development of GBS/MFS have been identified.
After the demonstration of anti-ganglioside antibodies in GBS/
MFS patient sera, and the subsequent identification of ganglioside 
mimics in Campylobacter LOS and of the specific host responses 
toward these epitopes, we now also demonstrate that the microbial 
gene repertoire is an important factor in the initiation of postin-
fectious autoimmune disease. The markers described in the cur-
rent communication may facilitate the search for mechanisms of 
microbial pathogenicity and be helpful in the development of new 
molecular diagnostic tools for identifying C. jejuni strains with 
an increased ability to induce GBS/MFS. Furthermore, increased 
insight into the biosynthesis of ganglioside-mimicking structures 
may ultimately lead to the development of new treatment strate-
gies and interventions (30).
Methods
C. jejuni strains. Seventeen GBS-associated and 4 MFS-associated C. jejuni 
strains used in this study were isolated from GBS/MFS patients from 
The Netherlands and Belgium between 1991 and 1999 (10). GB13 and 
GB26 were cultured from the diarrheal stools of family members of 2 GBS 
patients (31). Twenty-one control C. jejuni strains were isolated from spo-
radic Dutch enteritis patients without neurological symptoms between 
1990 and 1999 (8). Ten reference C. jejuni Penner serotypes (HS:1, HS:2, 
HS:3, HS:4, HS:10, HS:19, HS:23, HS:35, HS:36, and HS:64) and the 
“genome” strain NCTC 11168 (19) were also included as controls for the 
PCR tests. Characterization of the isolates by phenotypic and molecu-
lar methods showed that no clustering of GBS/MFS–associated strains 
occurred when these were compared with control strains (10, 12).
Growth conditions and DNA isolation. For PCR analysis, C. jejuni strains were 
cultured for 24–48 hours on blood agar plates in a microaerobic atmo-
sphere at 37°C. DNA was isolated using the Wizard Genomic DNA Purifi-
cation Kit (Promega Corp.).
For other experiments, C. jejuni WT strains were grown at 37°C on 
Mueller-Hinton agar plates supplemented with Modified Preston Cam-
pylobacter Selective Supplement (MPCSS; product code SR0204E; 
Oxoid Ltd.) in a microaerobic atmosphere. The mutant strains were 
grown on Mueller-Hinton agar plates supplemented with MPCSS and 
chloramphenicol, at a concentration of 20 μg/ml. For cloning, the E. coli 
strain JM109 (Promega Corp.) was grown on 2YT agar with 40 μg/ml 
ampicillin and 20 μg/ml chloramphenicol.
Serological methods. The ganglioside mimics in the LOS of the various 
strains were determined using polyclonal and monoclonal anti-ganglioside 
antibodies as described previously (8). An inventory was made for GM1-
like, GQ1b-like, and, collectively, other ganglioside-like structures.
Determination of the LOS locus class. To determine the class of LOS locus 
in C. jejuni strains, we developed specific primer sets for the classes A/B, 
C, D, and E, based on the DNA sequence of a gene unique to the LOS 
locus class(es) involved (Supplemental Table 1). To discern between 
classes A and B, we developed a primer set that was based on the DNA 
sequence of orf5-II. PCR assays were performed using a Thermocycler 60 
(Biomed GmbH) with a program consisting of 40 cycles of 1 minute at 
94°C, 1 minute at 52°C, and 2 minutes at 74°C. Per reaction, approxi-
mately 50 ng of template DNA was used in a buffer system consisting 
of 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 
0.1% Triton X-100, 0.2 mM of each of the deoxyribonucleotide triphos-
phates (Promega Corp.), and 0.2 U Super Taq polymerase (HT Biotech-
nology Ltd.). Timing needed to be adjusted for some of the amplifica-
tions. The selective PCR tests were validated with a panel of C. jejuni 
strains with a known LOS locus class.
Cloning and mutagenesis. The target genes (cst-II, orf10/orf11, and orf11) 
and approximately 700 bp of flanking sequence were amplified and 
cloned into the pGem-Teasy vector (Promega Corp.). Inverse PCR was 
used to introduce a BamHI restriction site and a deletion of approximately 
800 bp in the target genes (32). Inverse PCR products were digested with 
BamHI and ligated to the BamHI-digested chloramphenicol resistance 
(Cmr) cassette of pAV35 (33). After sequencing, the resulting constructs 
were electroporated into different C. jejuni strains, and recombinants 
were selected on Mueller-Hinton plates containing chloramphenicol (33). 
Junction PCR, with primers up- and downstream of the area involved in 
the homologous recombination, and primers in the Cmr cassette, was 
performed to confirm double crossover events and to assess the orienta-
tion of the resistance cassette.
Mass spectrometric analysis. Overnight growths from 1 agar plate 
were treated as described by Szymanski et al. (34) except that we used 
proteinase K at 60 μg/ml, RNase A at 200 μg/ml, and DNase I at 100 
μg/ml. The O-deacylated LOS samples were analyzed by capillary 
electrophoresis coupled with electrospray ionization mass spectrometry 
(CE-ESI-MS) as described by St. Michael et al. (35).
SDS-PAGE and Western blotting. Fresh overnight cultures of GB11 WT and 
mutant strains were harvested in PBS and lysed by sonification. To visual-
ize both protein and LOS fractions, the cell lysates were electrophoresed 
on 11% SDS-PAGE gels. To visualize the LOS fraction only, cell lysates 
were treated with proteinase K (1 mg/ml) for 2 hours at 65°C and 
electrophoresed on 15% SDS-PAGE gels. Gels were silver-stained to visual-
ize LOS cores, or the gels were blotted onto nitrocellulose. GB11 patient 
serum was used at a dilution of 1:2,500, and peroxidase-conjugated cholera 
toxin (Sigma-Aldrich) was used at a concentration of 1 μg/ml.
Mouse immunization experiments. This research was approved by the Animal 
Care and Use Committee, Dokkyo University School of Medicine (approval 
no. 00-22). Mice were treated according to the Guidelines for the Care and 
Use of Laboratory Animals of Dokkyo University School of Medicine. Mice 
lacking GM2/GD2 synthase as well as GM1 and GD1a (36) were immu-
nized i.p. several times at 2-week intervals with 1 mg of each lyophilized 
C. jejuni dissolved in 100 μl keyhole limpet hemocyanin solution, mixed 
with 100 μl CFA. One week after the final inoculation, blood samples were 
taken from the tail vein. Serum IgG antibodies to GM1, GD1a, and asialo-
GM1 were measured by an ELISA (37). The mean absorbance value for 
triplicate reference wells without antigen was subtracted from the mean 
value for triplicate sample wells with the antigen.
Statistical analysis. Statistical analysis was performed with InStat (version 
2.05a; GraphPad Software Inc.) using 2 × 2 contingency tables. Fisher’s 
exact tests were executed and 2-sided P values determined. Associations 
were considered significant at P < 0.05.
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